GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.

The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.

March 27 (Reuters) - AstraZeneca said on Friday its experimental respiratory treatment tozorakimab showed a meaningful ...

Shares of AstraZeneca rose on Friday after the drugmaker reported positive results from late-stage clinical trials of its ...

Whatever the reasons, AstraZeneca has emerged as the first IL-33 player to show consistent efficacy. Sanofi and Regeneron ...

Tozorakimab met the primary goal in two late-stage clinical trials, reducing the rate at which patients’ symptoms worsened, ...

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares rose 3% to 14,230p, placing the drugmaker at the top of the FTSE 100 leaderboard ...

The diabetes drugs, which usually cost about $525, are listed on TrumpRx starting around $55. The COPD inhaler drops from about $276 to $35, according to the White House. “Those are pretty significant ...

GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate that as of 2019, about 400 million people around ...

The White House said Friday it’s adding three drugs for diabetes and lung disease to the self-pay platform TrumpRx, as the ...

By Pushkala Aripaka, Nithyashree R B and Maggie Fick March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced ...